About this event

  • Date and time Wed 17 Nov 2021 from 8:50am to 18 Nov 2021 at 6:00pm
  • Location Online
  • Organised by Nephrology

This two-day international webinar is composed of a multi-professional faculty reflecting the multi-systemic nature of vasculitis and autoinflammation. Comprehensive updates on UKIVAS group activities, along with clinical and research advances in the field of vasculitis and autoinflammation will also be addressed.

This webinar is a collaboration between the Nephrology Section of the Royal Society of Medicine and UKIVAS

All specialities interested in the management of vasculitis and autoimmunity are invited to attend including both paediatric and adult medicine.

This webinar will:   

  • Describe UKIVAS registry activity with an outline of data linkage projects 
  • Examine recent service development, quality improvement initiatives and multi-professional communication networks 
  • Provide updates on bioresource, basic science and clinical research 
  • Outline advances in COVID-19 management and the impact of the pandemic on patients with vasculitis 
  • Learn of newer therapies, steroid minimisation approaches and trial pathways across a broad range of the vasculitides 
  • Highlight advances in paediatric vasculitis and communication  

CPD learning applied. 

Join in the conversation online using #RSMNephrology

Follow us on Twitter: @RoySocMed

 

Tickets

Standard pricing available until 17 November 2021.

Member

RSM Fellow
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
RSM Associate
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
RSM Retired Fellow
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
RSM Trainee
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
RSM Student
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2

Non - Member

Consultant / GP
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
AHP / Nurse / Midwife
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
Non Healthcare Professional
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
Trainee
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2
Student
Day 1 Day 2
£0.00 Day 1
£0.00 Day 2

Agenda

Day 1 - View the programme

Welcome address

Dr Allyson Egan, Chair Care Pathways UKIVAS and Past President, Nephrology Section, Royal Society of Medicine and Dr Stephen McAdoo, Treasurer, UKIVAS, and President, Nephrology Section, Royal Society of Medicine

UKIVAS introduction and welcome

Professor Neil Basu, Co-Chair UKIVAS, Professor of Musculoskeletal Medicine and Vasculitis, University of Glasgow and Professor Mark Little, Co-chair UKIVAS, Professor of Nephrology and Consultant Nephrologist, Trinity College Dublin

Session one: Vasculitis registries and data bases

Chairs: Professor Neil Basu and Dr Reem Aljayyousi, Consultant Nephrologist, University Hospital of Leicester NHS Trust

An update on the UKIVAS Registry

Dr Ruth Pepper, Consultant Nephrologist, Royal Free Hospital, Associate Professor, University College London

Scientific Monitoring Working Group update

Dr Silke R Brix, Consultant Nephrologist, Manchester NHS Foundation Trust

AAV and LVV outcomes in the Scottish population: A national data linkage study

Dr Rosemary Hollick, Senior Clinical Lecturer, Honorary Consultant Rheumatologist, University of Aberdeen

UKIVAS linkage to the national disease registration service in England

Dr Fiona Pearce, Clinical Associate Professor, Faculty of Medicine and Health Sciences, University of Nottingham

UKIVAS COVID Registry update

Dr Matthew Rutherford, Clinical Research Fellow, University of Glasgow

Air pollution and systemic vasculitis risk

Mr Enock Havyarimana, Marie-Sklodowska Curie Early Stage Fellow, University of Glasgow

UVB exposure and ANCA vasculitis disease activity – increasing power by leveraging EU registries

Professor Mark Little and Dr Jennifer Scott, Wellcome-HRB Irish Clinical Academic Training Fellow, Trinity College Dublin

Comfort break

Session two: Vasculitis in the COVID-19 era

Chairs: Dr Fiona Pearce and Dr Stephen McAdoo

Vasculitis services during the COVID-19 pandemic: Characterising changing practices across the United Kingdom and Ireland

Dr Allyson Egan

Using whole population data to describe COVID-19 outcomes in rare autoimmune rheumatic disease: the RECORDER project collaboration with NCARDRS

Dr Megan Rutter, Clinical Research Fellow, University of Nottingham, National Congenital Anomaly and Rare Disease Registration Service (NCARDRS)

Humoral and T cell responses to natural infection and covid vaccination in patients receiving immunosuppression

Dr Maria Prendecki, Clinical Lecturer, Imperial Vasculitis Centre, Imperial Collge London

COVID-19 vaccination in vasculitis patients on rituximab

Dr Matthew Rutherford

PIMS-TS

Professor Paul Brogan, Professor of Vasculitis and Consultant Paediatric Rheumatologist, Great Ormond Street Hospital for Children and University College London Institute of Child Health

COVID-19 infection in immunosuppressed populations

Dr Rachel Jones, Consultant Nephrologist, Vasculitis and Lupus Unit, Addenbrooke’s Hospital, University of Cambridge and Dr Rona Smith, Senior Research Associate and Honorary Consultant Nephrologist, Vasculitis and Lupus Unit, Addenbrooke’s Hospital, University of Cambridge

Lunch

Session three: ANCA negative vasculitis and autoinflammation

Chairs: Professor Helen Lachmann, Professor of Medicine and Honorary Consultant Nephrologist, Clinical Lead National Amyloidosis Centre, University College London and Royal Free Hospital London NHS Foundation Trust and Dr Andreas Kronbichler, Department of Medicine, University of Cambridge

VEXAS Syndrome and beyond: Somatic mutations in rheumatological diseases

Dr Peter Grayson, Tenure Track Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA

Deficiency of adenosine deaminase 2 (DADA2) diagnostic flags and treatment options

Dr Taryn Youngstein, Consultant Rheumatologist, Imperial Vasculitis Centre, Imperial College Healthcare NHS Trust

HAVEN: Hydroxychloroquine in ANCA vasculitis evaluation

Professor David D’Cruz, Consultant Rheumatologist, The Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust

Talk title to be confirmed

Speaker to be confirmed

Behcet’s Syndrome: Current diagnosis and management

Professor Omer Karadag, Director of Hacettepe Vasculitis Research Centre, Sihhiye-Ankara, Turkey, Consultant, Department of Internal Medicine Division of Rheumatology, Faculty of Medicine, Hacettepe University, Sihhiye-Ankara, Turkey

Cryoglobulinemia vasculitis

Professor Benjamin Terrier, Professeur des Universites-Praticien Hospitalier, Universite de Paris, Service de Medecine Interne, Hopital Cochin

Comfort break

Session four: Service development in vasculitis and autoinflammation

Chairs: Dr Rennie Rhee, Assistant Professor of Medicine, Division of Rheumatology, Hospital of the University of Pennsylvania and Dr Chee Kay Cheung, Consultant Nephrologist, Honorary Senior Lecturer, University of Leicester NHS Trust

Delivering the recommendations of the Getting it Right First Time (GIRFT) national report for rheumatology: opportunities for vasculitis care

Dr Peter Lanyon, Nottingham University Hospitals NHS Trust and Joint Lead, GIRFT Rheumatology Workstream, NHS England and NHS Improvement

Characterising AAV and LVV vasculitis services across the United Kingdom and Ireland – priorities for collaborative care

Dr Allyson Egan and Dr Rosemary Hollick

‘Fever’ in the time of COVID-19: Delivery of a nationally commissioned service

Professor Helen Lachmann

Session five: Cases and panel discussion

Panel discussion

Chairs: Dr Lisa Willcocks, Consultant Nephrologist, Cambridge University Hospital, Cambridge

Dr Giacomo Emmi, Clinical Immunologist, Assistant Professor of Internal Medicine, University of Firenze, Careggi University Hospital, Firenze, Italy

Panel: Professor Helen Lachmann, Dr Stephen McAdoo, Dr Rachel Jones, Dr Taryn Youngstein, Dr Rona Smith

Concluding remarks
Close of meeting
Day 2 - View the programme

Welcome and introduction

Dr Allyson Egan, Chair Care Pathways UKIVAS, Past President, Nephrology Section, Royal Society of Medicine and Dr Stephen McAdoo, Treasurer, UKIVAS, President, Nephrology Section, Royal Society of Medicine

Session one: Vasculitis: Cellular pathways, molecules and therapeutics

Chairs: Dr Paul Lyons, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge and Dr Tina Chrysochou, Past-President, Nephrology Section, Royal Society of Medicine, Consultant Nephrologist, Salford Royal Hospital NHS Foundation Trust

Talk title to be confirmed

Speaker to be confirmed

Platelets more than markers of inflammation in AAV

Professor Alan Salama, Professor of Nephrology, University College London Centre for Nephrology, Royal Free Hospital

B cell depletion in tissue after rituximab for AAV

Dr Mark McClure, Renal Registrar and Vasculitis Research Fellow, Cambridge University Hospital

Single cell transcriptomics of postnasal space lymphoid tissue to investigate tissue-based immunity in eosinophilic granulomatosis with polyangiitis

Mr Matthew Coates, Wellcome Trust ENT-Vasculitis Clinical Research Fellow, University of Cambridge

Longitudinal impact of anti-IL 5 therapy in eosinophilic granulomatosis with polyangiitis - update on UKIVAS Care Pathways working group

Dr Allyson Egan

IgG4-related disease

Professor Augusto Vaglio, Nephrology and Dialysis Unit, Meyer Children’s Hospital and Department of Biomedical, Experimental and Clinical Sciences, University of Firenze

Comfort break

Session two: Patient perspectives

Chairs: Professor Lorraine Harper, Professor of Nephrology, University of Birmingham and Professor Charles Pusey, Emeritus Professor of Medicine, Imperial College London

Living with vasculitis – what matters most?

Patient perspective panel discussion

Session three: Steroid minimisation and patient reported outcomes

Chairs: Dr Jackie Andrews, Medical Director, Harrogate and District NHS Foundation Trust and Dr Peter Lanyon, Nottingham University Hospitals NHS Trust and Joint Lead of the GIRFT Rheumatology Workstream

Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective

Dr Joanna Tieu, Clinical Research Fellow, Faculty of Health and Medical Sciences, University of Adelaide and Professor Catherine Hill, Clinical Professor, Head of Rheumatology Unit, The Queen Elizabeth Hospital, Staff Specialist, Royal Adelaide Hospital, University of Adelaide, President Australian Rheumatology Association

Glucocorticoid impact and development of the Steroid Patient Reported Outcome (PRO)

Dr Susan Bridgewater, Research Associate, University of West England and Dr Joanna Robson, Consultant Senior Lecturer, Rheumatology, Centre for Health and Clinical Research, University of West England

Quantifying the risks of glucocorticoid toxicity – there is no safe ‘steroid’ dose

Speaker to be confirmed

Sugar rush: What should we do about steroid-induced diabetes?

Dr Sarah Mackie, Associate Professor, Vascular Rheumatology, University of Leeds, Honorary Consultant Rheumatologist, Leeds Teaching Hospital NHS Trust

Panel discussion

Professor Catherine Hill, Dr Joanna Tieu, Dr Susan Bridgewater, Dr Joanna Robson and Dr Sarah Mackie

Session four: AAV Management 2021

Chair: Professor Ingeborg Bajema, Professor of Pathology, Leiden University Medical Centre

 

 

AAV therapy: Where are we going

Professor David Jayne, Professor of Clinical Autoimmunity, Director of the Vasculitis and Lupus Unit, Addenbrooke’s Hospital, University of Cambridge

Lunch

Session five: ANCA associated vasculitis and anti-glomerular basement membrane disease

Chairs: Professor Geetha Duvuru, Professor of Medicine, Johns Hopkins University School of Medicine and Professor Alan Salama, Professor of Nephrology, University College London Centre for Nephrology, Royal Free Hospital

Update on Education Working Group

Dr Nina Brown, Consultant Nephrologist, Salford Royal Hospital NHS Foundation Trust

Renal manifestations of vasculitis in children

Dr Louise Oni, Senior Lecturer, Paediatric Nephrology and Honorary Consultant Paediatric Nephrologist, University of Liverpool

In vivo degradation of autoantibodies using IdeS (imlifidase) as a treatment for anti-GBM disease

Professor Marten Segelmark, Skane University Hospital and Lund University, Sweden

How do we prevent accelerated atheromatous disease in patients with inflammatory kidney disease?

Dr Marilina Antonelou, Council Member, Nephrology Section, Royal Society of Medicine, Renal Registrar, Royal Free Hospital

Combination treatment with plasma exchange, cyclophosphamide and rituximab for severe ANCA vasculitis

Dr Kavita Gulati, Clinical Research Fellow, Imperial College Healthcare NHS Trust

Utility of interval kidney biopsy in ANCA-associated vasculitis

Dr Gavin Chapman, Internal Medicine Trainee, Royal Infirmary of Edinburgh

Comfort break

Session six: Large vessel vasculitis

Chairs: Professor Ann Morgan, Professor of Molecular Rheumatology, Honorary Consultant Rheumatologist, University of Leeds and Dr James Peters, Reader in Rheumatology, Imperial College London

Diagnostic and therapeutic advancement in Takayasu arteritis

Professor Justin Mason, Professor of Vascular Rheumatology, National Heart and Lung Institute, Imperial College London

Epidemiology and pathogenesis of GCA – insights from the UKGCA consortium

Professor Ann Morgan

GCA guideline highlights

Dr Sarah Mackie

BIOVAS – clinical trial enrolment for ANCA negative vasculitides

Dr Maria King, Senior Clinical Trials Co-ordinator, Cambridge University Hospital NHS Foundation Trust

The GCA PRO: A patient reported outcome for clinical trials and practice

Dr Joanna Robson, Consultant Senior Lecturer in Rheumatology, Centre for Health and Clinical Research, University of West England

Session seven: Cases and panel discussion

Panel discussion

Panel: Professor Kenneth J Warrington, Chair, Division of Rheumatology, Director, Vasculitis Clinic, John F. Finn MN Arthritis Foundation Professor of Medicine, Mayo Clinic College of Medicine and Science, Professor Maria C Cid, University of Barcelona, Senior Consultant Department of Autoimmune Diseases, Hospital Clinic, Senior Group Leader, Institute d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS) Barcelona, Dr Sarah Mackie, Dr Joanna Robson, Professor Justin Mason

Concluding remarks
Close of meeting

Location

Online

Disclaimer: All views expressed in this live stream are of the speakers themselves and not of the RSM nor the speaker's organisations.

Special rates for difficult times 
The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s ​weekly COVID-19 Series ​webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.

Registration for this live stream will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted.

This live stream will be available for registered delegates 30 days after on Zoom. The link will be sent 24 hours after the webinar takes place. 

This live stream will be recorded and stored by the Royal Society of Medicine and may be  distributed  in future on various internet channels. 

Man searching computer

Join the RSM and get unlimited digital learning and e-resources access

The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy unlimited digital learning any time you need and access to e-journals, e-books and 6 huge medical databases to support your clinical decision-making and research.

Our e-resources are updated continuously to ensure you receive the cutting edge knowledge you need. 

 

Become a member